New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:31 EDTSNN, MDT, COVSmith & Nephew slips after Medtronic agrees to acquire Covidien
Shares of U.K. medical device maker Smith & Nephew (SNN) are down nearly 2% in pre-market trading in New York after Medtronic (MDT) announced this weekend that it has agreed to acquire Irish device maker Covidien (COV) in a cash-and-stock transaction valued at approximately $42.9B. Note that on June 4 Bloomberg had reported that Medtronic was weighing a takeover bid for Smith & Nephew, which would have allowed the U.S. company to move its tax domicile to the U.K.
News For SNN;MDT;COV From The Last 14 Days
Check below for free stories on SNN;MDT;COV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:51 EDTCOV, MDTOECD looks to close tax loopholes with new proposals
Subscribe for More Information
08:07 EDTMDTMedtronic drug-coated baloon shows strong clinical, economic benefit
Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics, or TCT, conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon, or DCB, from Medtronic augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for peripheral artery disease, or PAD, in leg arteries above the knee. The IN.PACT Admiral DCB remains an investigational medical device in the United States. No drug-coated balloon has yet received approval from the FDA. The new data come from the real-world IN.PACT Global study, the largest and most rigorous post-market evaluation of its kind for any peripheral artery intervention, and from an ongoing economic outcomes analysis of the U.S. phase of the landmark IN.PACT SFA trial. Together, the results show that the IN.PACT Admiral DCB is not only clinically superior, but also cost-effective for the treatment of atherosclerotic lesions in the superficial femoral artery, or SFA, or proximal popliteal artery, or PPA, at 12 months compared to standard percutaneous transluminal angioplasty, or PTA.
07:31 EDTMDTEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
08:06 EDTMDTMedtronic announces SEEQ wearable cardiac monitoring system in U.S.
Subscribe for More Information
07:45 EDTMDTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:21 EDTMDTHeart Failure Society of America to hold annual meeting
Subscribe for More Information
07:04 EDTCOVCovidien announces start of enrollment in two neurovascular trials
Covidien announced the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the company’s advanced neurovascular solutions. Baptist Medical Center in Jacksonville, Florida, treated the first patient enrolled in the PREMIER Prospective study, an international Investigational Device Exemption clinical study to evaluate the Pipeline embolization device in smaller unruptured intracranial aneurysms. Separately, Baptist Health Lexington in Kentucky, enrolled the first patient in the STRATIS Registry for Endovascular Stroke Devices, which will evaluate the use of all Covidien market-released stroke devices. The PREMIER study will enroll up to 141 patients in 20 global sites and is designed to assess the safety and effectiveness of the Pipeline device in the treatment of unruptured, small and medium wide-necked intracranial aneurysms. The STRATIS Registry, a prospective, multi-center, non-randomized, observational registry designed to evaluate the use of Covidien endovascular stroke devices in patients diagnosed with an acute ischemic stroke. Covidien’s current endovascular stroke device in the U.S. is the Solitaire™ 2 revascularization device. As many as 60 U.S. sites are expected to participate in the STRATIS Registry, which will enroll up to 1,000 patients to collect clinical outcomes for interventional stroke patients in a real world setting.
September 13, 2014
16:47 EDTMDTMedtronic CoreValve provides positive outcomes out two years in risky patients
Medtronic announced new data showing that transcatheter aortic valve replacement, TAVR, with the CoreValve System continued to provide safe and effective treatment, while maintaining exceptional rates of survival out to two years for patients who were considered too ill or frail to have their aortic valves replaced through traditional open-heart surgery. Without treatment, these patients had a 50% chance of death at one year.
September 12, 2014
15:03 EDTMDTSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 11, 2014
10:00 EDTMDTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Airgas (ARG) initiated with a Neutral at Northcoast... CBOE Holdings (CBOE) initiated with a Buy at Deutsche Bank... CME Group (CME) initiated with a Buy at Deutsche Bank... Colfax (CFX) initiated with a Neutral at Northcoast... Corporate Office Properties (OFC) initiated with an Overweight at Capital One... Edwards Lifesciences (EW) initiated with a Buy at Sterne Agee... Energen (EGN) initiated with a Buy at Deutsche Bank... Goodrich Petroleum (GDP) initiated with an Outperform at Cowen... GreenHunter Resources (GRH) initiated with a Hold at Stifel... GrubHub (GRUB) initiated with a Market Perform at Barrington... Illinois Tool Works (ITW) initiated with a Neutral at Northcoast... IntercontinentalExchange (ICE) initiated with a Hold at Deutsche Bank... JD.com (JD) initiated with a Buy at Brean Capital... Lincoln Electric (LECO) initiated with a Buy at Northcoast... Live Nation (LYV) initiated with a Buy at Jefferies... Medtronic (MDT) initiated with a Neutral at Sterne Agee... Midstates Petroleum (MPO) initiated with a Market Perform at Cowen... NASDAQ (NDAQ) initiated with a Hold at Deutsche Bank... Newfield Exploration (NFX) initiated with an Outperform at Iberia... Newpark Resources (NR) initiated with an Outperform at Credit Suisse... Nuverra Environmental (NES) initiated with a Buy at Stifel... Palo Alto (PANW) initiated with a Buy at Roth Capital... Petrobras (PBR) initiated with an Outperform at Cowen... RSP Permian (RSPP) initiated with a Hold at Deutsche Bank... Sensata (ST) initiated with an Equal Weight at Morgan Stanley... Stage Stores (SSI) initiated with a Neutral at Credit Suisse... Synergy Resources (SYRG) initiated with an Outperform at Cowen... TE Connectivity (TEL) initiated with an Overweight at Morgan Stanley... Twitter (TWTR) initiated with a Buy at Canaccord... Walter Investment (WAC) initiated with an Underweight at Barclays... Washington REIT (WRE) initiated with an Equalweight at Capital One... Yandex (YNDX) initiated with a Buy at Canaccord... Yara International (YARIY) initiated with a Neutral at Credit Suisse.
08:11 EDTMDTMedtronic Noncompliant Balloon Dilatation Catheter receives FDA clearance
Medtronic announced the FDA 510(k) clearance and launch of the NC Euphora Noncompliant Balloon Dilatation Catheter. Following drug-eluting stent implantation to reopen a narrowed artery, a noncompliant balloon is inflated with high pressure to ensure that the stent is fully apposed in order to facilitate transfer of the drug to the artery wall. Stent under-expansion has been defined as a major risk factor for both artery re-narrowing, or restenosis, and the potential formation of blood clots, known as stent thrombosis. Postdilatation with noncompliant balloons has been recommended to overcome these complications and provide optimal stent expansion after stent placement.
September 10, 2014
16:09 EDTMDTMedtronic initiated with a Neutral at Sterne Agee
Target $68.
09:32 EDTMDTMedtronic announces first U.S. implants in CoreValve Evolut R study
Subscribe for More Information
September 9, 2014
06:42 EDTCOVLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 8, 2014
11:05 EDTCOVOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
September 5, 2014
11:47 EDTCOVOptions with increasing implied volatility
Subscribe for More Information
06:11 EDTMDTMedtronic Linq device being underappreciated, says Citigroup
Citigroup believes the Street is underestimating the near-term potential of Medtronic's recently released Reveal Linq insertable cardiac monitor. Citi thinks the combination of the U.S. Corevalve rollout and Linq contribution will drive sales to the high end of the company's 3%-5% guidance. The firm raised its price target for shares to $74 from $73 and keeps a Buy rating on the stock.
September 3, 2014
07:10 EDTMDTMedtronic announces CE Mark for CoreValve Evolut R System
Medtronic announced CE Mark for the 23 mm CoreValve Evolut R System for transcatheter aortic valve implantation, or TAVI. The novel, self-expanding valve and 14FR equivalent delivery system offers new capabilities that advance valve performance and deliverability during the procedure, while providing the option to recapture and reposition the valve during deployment phase, if needed.The novel system consisting of the CoreValve Evolut R transcatheter aortic valve and the EnVeo(TM) R Delivery Catheter System is designed for first-time positioning accuracy and also offers a new InLine Sheath that significantly reduces the profile to the lowest on the market; a smaller profile size is believed to minimize the risk of major vascular complications. The new valve is anatomically designed to increase conformability at the annulus for optimal annular fit and sealing, while maintaining supra-annular valve position for improved hemodynamic performance.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use